Disease Analyzer - OMOP

First published: 01/02/2024

Last updated: 17/10/2024

Data source | Outdated | Human | Primary care medical records

Administrative details

Administrative details

Data source ID

1111130

Data source acronym

DA France

Data holder

IQVIA

Data source type

Primary care medical records

Main financial support

Funding by own institution

Funding from industry or contract research

Care setting

Primary care – GP, community pharmacist level

Data source qualification

If the data source has successfully undergone a formal qualification process (e.g., from the EMA, ISO or other certifications), this should be described.

No

Data source website

https://www.iqvia.com/solutions/real-world-evidence/real-world-data-and-insights

Contact details

Sarah Seager sarah.seager@iqvia.com

Main

sarah.seager@iqvia.com

Data source regions and languages

Data source countries

France

Data source languages

French

Data source establishment

Data source established

15/06/1997

Data source time span

First collection: 01/01/2012

The date when data started to be collected or extracted.

Publications

Data source publications

Association of Hemoglobin A1c Levels with Use of Sulfonylureas, Dipeptidyl Peptidase 4 Inhibitors, and Thiazolidinediones in Patients with Type 2 Diabetes Treated With Metformin Analysis From the Observational Health Data Sciences and Informatics Initiative JAMA Network Open. 2018;1(4):e181755.

Studies

List of studies that have been conducted using the data source

Prescribing of zolpidem in the primary care setting in France, Germany and the UK during 2012. (Prescribing of zolpidem in IMS Germany/France/UK)

A Nested Case-control Post-authorization Safety Study of Etoricoxib and Other Non-steroidal Anti-inflammatory Therapies in a Cohort of Patients with Ankylosing Spondylitis (AS) in the UK, France and Germany (MK-0663-163)

Indications for systemic fluoroquinolone prescribing in Europe: a descriptive population based study

Tramadol prescribing: a drug utilisation study using electronic data from France, Germany and the UK

A Joint Drug Utilisation Study (DUS) of valproate and related substances, in Europe, using databases

Use of ondansetron in pregnant female patients in the IMS Disease Analyzer databases in France and Germany (Ondansetron use pregnancy)

Hydroxychloroquine safety and potential efficacy as an antiviral prophylaxis in light of potential wide-spread use in COVID-19: a multinational, large-scale network cohort and self-controlled case series study

Utilisation of dulaglutide in European countries: A cross-sectional, multi-country and multi-source drug utilisation study using electronic health record databases (H9X-MC-B010)

Trends in prescriptions of valproate and valpromide for bipolar disorder in IMS France and IMS Germany between 2010 and June 2016 and in UK THIN between 1999 and 2015

Prevalence of hypereosinophilic syndrome (HES) in the paediatric population in EU (Hypereosinophilic syndrome in children)

Glucocorticoid-induced osteoporosis (GIOP): prescription patterns of glucocorticoids in paediatric patients

Prevalence of narcolepsy in two European countries - France and Germany

Incidence rates of morphoea, systemic sclerosis and scleroderma

Background incidence rates of Interstitial Lung Disease

Population incidence rates of pemphigoid in six European countries

Immune thrombocytopenia following vaccination with DTaP-IPV or TdaP-IPV in children

Prevalence of palmoplantar psoriasis and pustular psoriasis in children

Drug utilisation study of macrolide-containing medicinal products during pregnancy

Prevalence of primary and secondary arterial hypertension in children and treatment with angiotensin II receptor blockers

Prevalence of multiple myeloma

Prevalence of immunocompromised patients with a diagnosis of cytomegalovirus infection

Prevalence of Acute Liver Injury

Incidence of phimosis and paraphimosis in patients treated with SGLT2 inhibitors

DARWIN EU® - Characterising interstitial lung disease in Europe

DARWIN EU® - Prescription trends of ketamine and esketamine

Data elements collected

The data source contains the following information

Disease information

Does the data source collect information with a focus on a specific disease? This might be a patient registry or other similar initiatives.

No

Rare diseases

Are rare diseases captured? In the European Union a rare disease is one that affects no more than 5 people in 10,000.

No

Pregnancy and/or neonates

Does the data source collect information on pregnant women and/or neonatal subpopulation (under 28 days of age)?

Yes

Hospital admission and/or discharge

No

ICU admission

Is information on intensive care unit admission available?

No

Cause of death

Not Captured

Prescriptions of medicines

Captured

Prescriptions vocabulary

RxNorm

Dispensing of medicines

Captured

Dispensing vocabulary

other

RxNorm

Dispensing vocabulary, other

CVX

Advanced therapy medicinal products (ATMP)

Is information on advanced therapy medicinal products included? A medicinal product for human use that is either a gene therapy medicinal product, a somatic cell therapy product or a tissue engineered products as defined in Regulation (EC) No 1394/2007 [Reg (EC) No 1394/2007 Art 1(1)].

No

Contraception

Is information on the use of any type of contraception (oral, injectable, devices etc.) available?

Yes

Indication for use

Does the data source capture information on the therapeutic indication for the use of medicinal products?

Captured

Indication vocabulary

SNOMED

Medical devices

Is information on medicinal devices (e.g., pens, syringes, inhalers) available?

No

Administration of vaccines

No

Procedures

Does the data source capture information on procedures (e.g., diagnostic tests, therapeutic, surgical interventions)?

Captured

Procedures vocabulary

SNOMED

Healthcare provider

Is information on the person providing healthcare (e.g., physician, pharmacist, specialist) available? The healthcare provider refers to individual health professionals or a health facility organisation licensed to provide health care diagnosis and treatment services including medication, surgery and medical devices.

Yes

Clinical measurements

Is information on clinical measurements (e.g., BMI, blood pressure, height) available?

Yes

Genetic data

Are data related to genotyping, genome sequencing available?

Not Captured

Biomarker data

Does the data source capture biomarker information? The term “biomarker” refers to a broad subcategory of medical signs (objective indications of medical state observed from outside the patient), which can be measured accurately and reproducibly. For example, haematological assays, infectious disease markers or metabolomic biomarkers.

Captured

Biomarker data vocabulary

Other

Biomarker vocabulary, other

LOINC,SNOMED,Cancer modifier

Patient-reported outcomes

Is information on patient-reported outcomes (e.g., quality of life) available?

No

Patient-generated data

Is patient-generated information (e.g., from wearable devices) available?

Yes

Units of healthcare utilisation

Are units of healthcare utilisation (e.g., number of visits to GP per year, number of hospital days) available or can they be derived? Units of healthcare utilisation refer to the quantification of the use of services for the purpose of preventing or curing health problems.

Yes

Unique identifier for persons

Are patients uniquely identified in the data source?

Yes

Diagnostic codes

Captured

Diagnosis / medical event vocabulary

SNOMED

Medicinal product information

Captured

Medicinal product information collected

Active ingredient(s)

Brand name

Package size

Route of administration

Strength

Medicinal product vocabulary

RxNorm

Quality of life measurements

Captured

Quality of life measurements vocabulary

Not coded (Free text)

Lifestyle factors

Captured

Lifestyle factors

Other

Sociodemographic information

Captured

Sociodemographic information collected

Gender

Quantitative descriptors

Population Qualitative Data

Population age groups

Paediatric Population (< 18 years)

Children (2 to < 12 years)

Adolescents (12 to < 18 years)

Adults (18 to < 46 years)

Adults (46 to < 65 years)

Elderly (≥ 65 years)

Adults (65 to < 75 years)

Adults (75 to < 85 years)

Adults (85 years and over)

Estimated percentage of the population covered by the data source in the catchment area

3%

Description of the population covered by the data source in the catchment area whose data are not collected (e.g., people who are registered only for private care)

General population

Family linkage

Family linkage available in the data source permanently or can be created on an ad hoc basis

Ad hoc

Population

Population size

6.285.423

Active population size

947.234

Population by age group

Age group	Population size	Active population size
Paediatric Population (< 18 years)	1.458.377	188.048
Children (2 to < 12 years)	871.516	109.419
Adolescents (12 to < 18 years)	425.875	60.035
Adults (18 to < 46 years)	2.434.564	305.697
Adults (46 to < 65 years)	1.319.153	231.950
Elderly (≥ 65 years)	1.073.329	221.539
Adults (65 to < 75 years)	539.597	114.096
Adults (75 to < 85 years)	337.082	72.802
Adults (85 years and over)	196.650	34.641

Median observation time

Median time (years) between first and last available records for unique individuals captured in the data source

229,00

Median time (years) between first and last available records for unique active individuals (alive and currently registered) capt

1.338,00

Data flows and management

Access and validation

Governance details

Documents or webpages that describe the overall governance of the data source and processes and procedures for data capture and management, data quality check and validation results (governing data access or utilisation for research purposes).

https://www.pharmacoepi.org/resources/policies/guidelines-08027/

Biospecimen access

Are biospecimens available in the data source (e.g., tissue samples)?

No

Access to subject details

Can individual patients/practitioners/practices included in the data source be contacted?

No

Description of data collection

Anonymized patient records collected from patient management software used by GPs to document patients’ clinical records

Event triggering registration

Event triggering registration of a person in the data source

Practice registration

Event triggering de-registration of a person in the data source

Death

Emigration

Loss to follow up

Practice deregistration

Event triggering creation of a record in the data source

Physician encounter

Data source linkage

Linkage

Is the data source described created by the linkage of other data sources (prelinked data source) and/or can the data source be linked to other data source on an ad-hoc basis?

No

Data management specifications that apply for the data source

Data source refresh

Quarterly

Informed consent for use of data for research

Not Required

Possibility of data validation

Can validity of the data in the data source be verified (e.g., access to original medical charts)?

No

Data source preservation

Are records preserved in the data source indefinitely?

No

Data source preservation length (years)

10 years

Approval for publication

Is an approval needed for publishing the results of a study using the data source?

No

Data source last refresh

01/12/2022

Common Data Model (CDM) mapping

CDM mapping

Has the data source been converted (ETL-ed) to a common data model?

Yes

CDM Mappings

CDM name

OMOP

CDM website

https://www.ohdsi.org/Data-standardization/

Data source ETL CDM version

5.3.1

Data source ETL frequency

4,00 months

Data source ETL status

Completed